To investigate the duration and kinetics of immunoglobulin M (IgM) and IgG antibodies against Borrelia burgdorferi in serum after treatment of Lyme borreliosis, consecutive serum samples from 30 seropositive patients with erythema migrans and 91 seropositive patients with neuroborreliosis were analyzed with a capture IgM enzyme-linked immunosorbent assay (ELISA) and an indirect IgG ELISA, both using B. burgdorferi flagella as the antigen. All the patients improved after treatment: 97 patients had a complete clinical recovery, while 24 patients had sequelae. The results showed that patients with erythema migrans and early neuroborreliosis more often initially had highly elevated IgM optical density (OD) values and low IgG OD values against B. burgdorferi, while the opposite was found in patients with late neuroborreliosis. During follow-up, the majority of patients had developed negative or significantly declining IgM ODs after 1 to 1.5 years but persistently positive IgM ODs were found up to 17 months after treatment of erythema migrans and 3 years after treatment of neuroborreliosis. IgG antibody levels declined more slowly and remained elevated to a larger extent, but more than half of the patients had developed negative IgG ODs within 5 years after therapy. However, positive IgG OD values were found after 9 to 10 years for patients treated for neuroborreliosis as well as erythema migrans. Both IgM and IgG antibodies against B. burgdorferi may persist for months to years after successful treatment of Lyme borreliosis. Consequently, a single serum sample with antibodies against B. burgdorferi must always be carefully evaluated and correlated to clinical symptoms.
Erythema migrans (EM), neuroborreliosis, arthritis, and acrodermatitis chronica atrophicans are different clinical manifestations of Lyme borreliosis, which may be diagnosed by the medical history and typical clinical findings (2, 3, 16, 18, 23, 24) . However, to confirm the diagnosis, serological methods, mainly the enzyme-linked immunosorbent assay (ELISA), are available and often necessary (10, 12, 22) .
Serological studies have shown seropositivity rates of 25 to 50% in patients with EM and 50 to 80% in patients with neuroborreliosis (9, 10, 14, 21, 22) . The diagnostic sensitivity of ELISA has been increased by the introduction of new antigens, e.g., the flagellum antigen (10, 14) , and capture ELISA instead of indirect ELISA for the immunoglobulin M (IgM) analysis (12) . An increase in test sensitivity is of importance for early diagnosis.
Although Lyme borreliosis in all stages is a treatable disease, doubts might be raised in clinical practice whether treatment is successful. One reason for persisting symptoms after antibiotic treatment is true treatment failure, but most probably incorrect diagnosis or symptoms due to irreversible tissue damage are more common causes (1, 19 recovery (7, 15, 17) . This may account for the high seropositivity rate among healthy people living in areas where the disease is endemic without a previous known history of Lyme borreliosis (8) . If Neuroborreliosis. A total of 91 patients with neuroborreliosis were included in the study. The diagnosis of neuroborreliosis was made on the basis of a typical clinical picture (n = 91), the presence of pleocytosis in cerebrospinal fluid (n = 91), and intrathecal antibody production against B. burgdorferi (n = 62). In the 29 patients without specific intrathecal antibody production at diagnosis, a majority of whom had a disease duration of less than 1 month, preceding or present EM (n = 8), positive IgM antibodies against B. burgdorferi in serum (n = 7), or both (n = 14) were required for inclusion. Clinical data from the 91 patients are presented in Table 2 .
ELISA. All serum samples, stored at -70°C, were analyzed with a capture IgM ELISA and an indirect IgG ELISA, both using B. burgdoiferi flagella as the antigen. The methods have earlier been described in detail (10, 12) . In brief, in the capture IgM ELISA the solid phase was coated with ,u-chain-specific rabbit anti-human IgM, binding to human IgM antibodies in sera diluted 1/200. B. burgdorferi-specific IgM antibodies reacted with the test antigen consisting of a B. burgdorferi flagellum-biotin-avidin-peroxidase complex. Bound flagella were visualized by the addition of O-phenylenediamine substrate. In the indirect IgG ELISA, microdilution plates were coated with purified B. burgdorferi flagella. Serum samples diluted 1/200 were added, and specific antibodies were bound. The binding was detected by the addition of peroxidaseconjugated rabbit anti-human IgG antibodies and O-phenylenediamine substrate. In both assays the optical density (OD) was read spectrophotometrically and cutoff was defined as the 98th percentile of OD values obtained among sera from 200 healthy controls and was 0.500 in the IgM ELISA and 0.180 in the IgG ELISA (10, 12) . Consecutive serum samples Table 3 . In summary, 9 of 21 initially IgG-positive patients (43%) became IgG negative during follow-up from 4 months to 9 years (median, 3 years). The remaining 12 patients (57%) still had positive IgG ODs after 3, 6, 12, 15, and 17 (n = 2) months and 2.5 (n = 2), 3 (n = 2), and 9 (n = 2) years of follow-up.
Retreated EM patients. Serum samples from two patients treated by a second antibiotic regimen showed declining IgM OD levels before retreatment. Both patients had negative IgG ODs.
Comparison of EM patients who recovered and those with sequelae. The only patient with persistent symptoms at follow-up (arthralgia 1 year posttreatment) became seronegative.
Among the 29 patients with a complete clinical recovery, 1 patient (3%) still had a positive IgM OD after 7 months, 3 patients (10%) were still positive by both IgM and IgG ELISA after 12 to 17 months (median, 15 months), and 9 patients (31%) had positive IgG ODs at follow-up after 3 months to 9 years (median, 2.5 years).
The remaining 16 patients (55%) without residual symptoms became seronegative during a follow-up time which varied from 4 months to 9 years (median, 3 years).
Neuroborreliosis. To illustrate the kinetics of the IgM and IgG ODs for patients with neuroborreliosis graphically (Fig. 2 (Fig. 4B) .
One other patient with meningoradiculitis and treated with i.v. pcG recovered completely. In the following summer, 9 months posttreatment, he developed EM and was treated with oral pcV. No simultaneous rise of the IgM or IgG OD levels was seen for this patient.
Comparison of neuroborreliosis patients who recovered and those with sequelae. Of the 23 patients with sequelae, one patient (4%) with extremity monoparesis still had an OD level positive for IgM against B. burgdorferi after 15 months. Eight patients (35%) with residual symptoms consisting of neuralgic pain and/or impaired sensitivity (n = 2), partial facial palsy (n = 3), reduced intellectual capacity (n = 2), and paraparesis (n = 1) were still positive by IgG ELISA when followed for 9 months to 10 years (median, 3 years, 9 months). The remaining 14 patients (61%) with sequelae became seronegative during follow-up of 3 months to 8 years (median, 2.5 years).
Of the 68 patients with a complete clinical recovery, 9 patients (13%) had positive IgM ODs when followed for 8 months to 3 years (median, 17 months). Six patients (9%) had were still positive by IgG ELISA when followed for 9 months to 10 years (median, 4 years). This included the patient (III [Fig. 3B] ) who was seronegative at 9 months of follow-up but showed a significant rise in IgG against B. burgdorferi after 18 months due to EM. The remaining 40 of 68 (59%) patients with a complete clinical recovery became seronegative during follow-up between 4 months and 10 years (median, 2 years).
DISCUSSION
A few previous studies have investigated the duration of seropositivity after Borrelia infection, and the results indicate that the IgG antibody response against B. burgdorferi may remain positive for years (4, 6, 8, 15, 20, 22) . Most of the earlier publications on this subject have concerned untreated patients with a spontaneous recovery (4, 15) or asymptomatic persons in epidemiological screening surveys (8, 20) . One publication has demonstrated specific IgM and IgG against B. burgdorferi for 2 to 3 years after antibiotic treatment of different Lyme disease manifestations (6), and another study has shown persistent IgG against B. burgdorferi in serum for several years after therapy of neuroborreliosis (22) . The present study also demonstrates that the serological response against B. burgdorferi may persist for years even after antibiotic treatment of EM and neuroborreliosis, although the specific antibody response decreases or vanishes over time. No earlier publication has demonstrated the kinetics of the antibody response after treatment of Lyme borreliosis for as long as 10 years or for such a large selection of patients.
As has been shown earlier, IgM and IgG antibodies against B. burgdorferi develop gradually and rather slowly during the disease before treatment (10, 12, 14, 22) . This is also demonstrated in the present study by Fig. 1 to 4 showing that patients with EM and early neuroborreliosis more often have initially (22) , while the decline of the IgG ODs after the start of therapy in the majority of patients was probably influenced by antibiotic treatment. Since the duration of both IgM and IgG positivity against B. burgdorferi after therapy may persist for a long time, other authors have suggested the measurement of cytokines to determine the effect of treatment (5). This suggestion is interesting and should be investigated further.
As demonstrated by the graphs, for a few patients, the IgM or IgG ODs seemed to rise slowly or remain stationary for months or even years after therapy, despite clinical recovery. Since the intervals between serum analyses of the patients differed in the present study, a long interval between pretreatment and posttreatment samples may give the false impression of a stable value even though there might have been an increase of the OD in between. Another explanation is of course a subclinical or an undiagnosed clinical reinfection causing a rise in the IgG OD. As seen with a few patients in the present study (Fig. 3B and 4B) , clinical reinfections of patients living in areas endemic to B. burgdorferi seem to be a reality.
Three patients in the present study developed EM months to years after treatment of neuroborreliosis. For two of these three patients, an increase of the IgG OD was measured. Since one patient developed a rise in IgG OD without symptoms, subclinical reinfections also seem to occur.
One patient (I [Fig. 3A] ) showed an increasing IgM OD 1.5 years after treatment. He initially had a complete clinical recovery and had developed neither any new symptoms of infection with B. burgdorferi nor symptoms of any other infection when the IgM rise was measured. No retreatment was given. The IgM kinetics for this patient are difficult to explain, but in the absence of additional symptoms treatment failure seems unlikely. On the other hand, as declining levels of IgM and/or IgG antibodies against B. burgdorferi were seen before retreatment of the five patients who received a second antibiotic course, it is doubtful that any of these cases should be judged as true treatment failures.
In conclusion, both IgM and IgG antibodies against B. burgdorferi may persist for months to years without signs of disease activity after treatment of Lyme borreliosis. The decrease of IgM and IgG ODs often seems to be slower than the clinical recovery, but it is likely that the declining tendency is influenced by antibiotic therapy. A positive measurement of antibody to B. burgdorferi in a single serum analysis for healthy persons or patients with dermatologic, neurologic, or joint diseases must always be carefully evaluated. Also, reinfection may maintain seropositivity.
